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Diagnostic accuracy of a low-cost, urine antigen, point-of-care 
screening assay for HIV-associated pulmonary tuberculosis 
before antiretroviral therapy: a descriptive study
Stephen D Lawn, Andrew D Kerkhoﬀ , Monica Vogt, Robin Wood
Summary
Background The diagnostic accuracy of sputum smear microscopy and routine chest radiology for HIV-associated 
tuberculosis is poor, and culture-based diagnosis is slow, expensive, and is unavailable in most resource-limited settings. 
We assessed the diagnostic accuracy of a urine antigen test Determine TB-LAM Ag (Determine TB-LAM; Alere, Waltham, 
MA, USA) for screening for HIV-associated pulmonary tuberculosis before antiretroviral therapy (ART).
Methods In this descriptive study, consecutive adults referred to a community-based ART clinic in Gugulethu 
township, South Africa, were all screened for tuberculosis by obtaining sputum samples for ﬂ uorescence microscopy, 
automated liquid culture (gold-standard test), and Xpert MTB/RIF assays (Cepheid, Sunnyvale, CA, USA) and urine 
samples for the Clearview TB-ELISA (TB-ELISA; Alere, Waltham, MA, USA) and Determine TB-LAM test. Patients 
with Mycobacterium tuberculosis cultured from one or more sputum samples were deﬁ ned as cases of tuberculosis. 
The diagnostic accuracy of Determine TB-LAM used alone or combined with sputum smear microscopy was compared 
with that of sputum culture and the Xpert MTB/RIF assay for all patients and subgroups of patients stratiﬁ ed by CD4 
cell count.
Findings Patients were recruited between March 12, 2010, and April 20, 2011. Of 602 patients enrolled, 542 were able to 
provide one or more sputum samples, and 94 had culture-positive tuberculosis (prevalence 17·4%, 95% CI 14·2–20·8). 
Complete results from all tests were available for 516 patients (median CD4 count, 169·5 cells per μL; IQR 100–233), 
including 85 culture-positive tuberculosis, 24 of whom (28·2%, 95% CI 19·0–39·0) had sputum smear-positive disease. 
Determine TB-LAM test strips provided results within 30 min. Agreement was very high between two independent 
readers of the test strips (κ=0·97) and between the test strips and TB-ELISA (κ=0·84). Determine TB-LAM had highest 
sensitivity at low CD4 cell counts: 66·7% (95% CI 41·0–86·7) at <50 cells per μL, 51·7% (32·5–70·6) at <100 cells per μL, 
and 39·0% (26·5–52·6) at <200 cells per μL; speciﬁ city was greater than 98% for all strata. When combined with smear 
microscopy (either test positive), sensitivity was 72·2% (95% CI 46·5–90·3) at CD4 counts less than 50 cells per μL, 
65·5% (45·7–82·1) at less than 100 cells per μL, and 52·5% (39·1–65·7) at less than 200 cells per μL, which did not 
diﬀ er statistically from the sensitivities obtained by testing a single sputum sample with the Xpert MTB/RIF assay.
Interpretation Determine TB-LAM is a simple, low-cost, alternative to existing diagnostic assays for tuberculosis 
screening in HIV-infected patients with very low CD4 cell counts and provides important incremental yield when 
combined with sputum smear microscopy.
Funding Wellcome Trust.
Introduction
Tuberculosis is a leading cause of morbidity and 
mortality in patients accessing antiretroviral treatment 
(ART) programmes in sub-Saharan Africa and much of 
this disease remains unidentiﬁ ed.1–4 The high burden of 
disease in these often overcrowded clinical services also 
presents a substantial risk of nosocomial disease 
transmission.5 Intensiﬁ ed case ﬁ nding is therefore a 
key intervention in these settings,6,7 enabling early 
diagnosis and rapid initiation of treatment. However, 
case ﬁ nding among patients with advanced HIV-
associated immuno deﬁ ciency still presents a major 
challenge since the diagnostic accuracy of the most 
widely used diagnostic tools (sputum-smear microscopy 
and chest radiology) is poor and culture-based diag-
nosis is slow, expensive, and is mostly unavailable in 
resource-limited settings due to the complex technical 
infra structure required.8
We previously reported that the Xpert MTB/RIF assay 
(Cepheid, Sunnyvale, CA, USA) substantially increased 
case ﬁ nding compared with sputum-smear microscopy 
when used to routinely screen for tuberculosis in an ART 
service in Cape Town, South Africa, allowing rapid 
diagnosis of about two-thirds of culture-conﬁ rmed cases.9 
This assay represents a substantial technological advance 
in tuberculosis diagnostics that can be used in the clinical 
environment by operators with little technical training.10 
However, the assay has drawbacks: it is expensive, 
requires sophisticated hardware with annual servicing, 
must be linked to a personal computer, and requires an 
electricity supply. The assay has been endorsed by WHO11 
and yet implementation and scale-up is likely to be 
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hindered by the high cost, which might be judged 
prohibitive in many poor countries.
The need for a simple, low-cost, point-of-care assay for 
tuberculosis is great.12 We and others have described the 
usefulness of a simple, commercially available ELISA 
that detects lipoarabinomannan (LAM) in urine as 
a diagnostic test for tuberculosis.13–21 LAM is a 19 kDa 
lipopolysaccharide major cell-wall component of 
Mycobacterium tuberculosis22 that can be detected in urine 
of patients with pulmonary and extrapulmonary 
disease.20,21 Although the sensitivity of this assay (about 
10–20%) in non-HIV-infected individuals has been 
disappointing,20 moderate sensitivity and high speciﬁ city 
have been reported in HIV-infected individuals with 
advanced immunodeﬁ ciency,13,14 the very patients in 
whom tuberculosis is especially diﬃ  cult to diagnose.
In this study, we assess the diagnostic accuracy 
of a new point-of-care lateral-ﬂ ow urine test for 
lipoarabinomannan (LAM; Determine TB-LAM Ag 
[Determine TB-LAM] Alere, Waltham, MA, USA) and 
the most recent version of the commercially available 
Clearview TB ELISA (TB-ELISA; Alere, Waltham, MA, 
USA) for screening a cohort of patients for tuberculosis 
before starting ART in South Africa.
Methods
Patients
The ART service in Gugulethu township, Cape Town, 
South Africa, has previously been described in detail as 
has the major burden of tuberculosis in this service.2,23,24 
We did a descriptive study of consecutive HIV-infected 
patients newly referred to the clinic in Gugulethu 
township for ART. Patients were prospectively recruited 
and investigated at their ﬁ rst visit to the clinic. Patients 
were eligible for the study if they were older than 18 years 
of age, ART-naive, and had no current tuberculosis 
diagnosis. All participants provided written informed 
consent and the study was approved by the research 
ethics committees of the University of Cape Town, South 
Africa, and the London School of Hygiene & Tropical 
Medicine, UK. The study protocol was prespeciﬁ ed and 
was reported in conformity with the STAndards for the 
Reporting of Diagnostic accuracy studies.
Procedures
Demographic details were recorded and a standardised 
symptom-screening ques tionnaire was completed. Two 
sputum samples were requested from each patient: a 
spot specimen was obtained ﬁ rst followed by a second 
that was induced with nebulised 3% hypertonic saline. If 
necessary, both specimens were induced. Urine samples 
were also collected in sterile containers and stored at 
–20°C within 3 h of collection. Blood CD4 cell counts and 
plasma viral load were measured for all patients via the 
routine laboratory services. Chest radiographs were 
obtained for all patients except pregnant women and 
were assessed by an experienced investigator (SDL) 
certiﬁ ed in the use of the chest-radiograph reading and 
recording system.25,26 Radiographs were scored according 
to the presence of any radiographic abnormality 
consistent with (but not necessarily suggestive of) a 
diagnosis of tuberculosis. 
Sputum specimens were processed with standardised 
protocols and quality assurance procedures by a 
centralised accredited laboratory. After decontamination 
with N-acetyl-L-cysteine and sodium hydroxide, centri-
fuged sputum deposits underwent microscopy, and after 
resuspension in phosphate buﬀ er, equal volumes were 
tested by culture and the Xpert MTB/RIF assay. Smears 
stained with auramine O ﬂ uorescent stain were 
examined with ﬂ uorescence microscopy. All sample 
smears graded as scanty, 1+, 2+, and 3+ were deﬁ ned as 
smear-positive. Mycobacterial growth indicator tubes 
(MGIT; Becton Dickinson, Sparks, MD, USA) were 
inoculated and incubated for up to 6 weeks. Culture 
isolates positive for acid-fast bacilli were identiﬁ ed as 
M tuberculosis complex with the MTBDRplus assay (Hain 
Lifesciences, Nehren, Germany). Acid-fast bacilli that 
tested negative for M tuberculosis with the MTBDRplus 
assay were assumed to be non-tuberculous mycobacteria 
but were not speciated further. Xpert MTB/RIF and 
MTBDRplus assays were done according to the 
manufacturer’s instructions. Results of all tests were 
read by technologists who were masked to the outcomes 
of the other assays.
Frozen urine samples were defrosted and analysed for 
the presence of LAM with the commercially available 
Clearview TB ELISA with strict adherence to the 
manufacturer’s instructions. Urine samples were 
prepared by heating to 95–100°C for 30 min and, after 
cooling, were centrifuged at 10 000 rpm for 15 min. 
Supernatants were analysed in duplicate together with 
positive and negative controls. An optical density reading 
of 0·1 or higher above the negative control was scored as 
positive in accordance with the manufacturer’s 
instructions.
Urine samples were also tested in the laboratory with 
the Determine TB-LAM test (a single manufacturing lot 
#101102 was used). Samples were defrosted to ambient 
temperature. For each sample, 60 μL was applied to the 
sample pad at the bottom of the test strip. Between 
25 min and 35 min later, the test was read under ambient 
laboratory lighting conditions by two investigators (SDL 
and MV), who compared the test strips with a standardised 
reference card to facilitate reading. Each reader 
independently recorded the results, taking note of both 
the positive control bar and the sample test result. After 
comparison of the results, any discrepancies were 
discussed and the test strip reviewed within the 25–35 min 
time frame to reach consensus.
Statistical analysis
The study population was characterised with simple 
descriptive statistics and patients with and without 
For more on STARD see http://
www.stard-statement.org/
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tuberculosis were compared with the Wilcoxon rank-
sum test, t-test, χ²-square test, and Fisher’s exact test 
accordingly. Patients with M tuberculosis cultured from 
one or more sputum samples were deﬁ ned as cases of 
tuberculosis. Results from the TB-ELISA and the 
Determine TB-LAM strip tests were compared and the 
proportionate agreement and κ statistics were calculated. 
The sensitivity, speciﬁ city, and predictive values of the 
diﬀ erent tuberculosis diagnostic assays were calculated 
with 95% CIs. These parameters were also calculated for 
subgroups of patients stratiﬁ ed by CD4 cell count, WHO 
stage, symptoms, and radiological abnormalities. Venn 
diagrams were plotted to compare the diagnostic yields 
of the diﬀ erent tests. All statistical tests are two-sided at 
α=0·05.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Patients were recruited between March 12, 2010, and 
April 20, 2011, some of whom have previously been 
described.9 Of 604 consecutive eligible patients who were 
invited, 602 agreed to participate. Urine samples were 
obtained from 595 (99%) patients. Sputum samples were 
obtained from 542 (90%) patients, and M tuberculosis was 
cultured from one or both samples from 94 patients. 
Thus, the prevalence of pulmonary tuberculosis in 
patients from whom sputum could be obtained was 17·3% 
(95% CI 14·2–20·8). The prevalence of tuberculosis in 
patients with CD4 counts of less than 100 cells per μL 
was 26·4% (95% CI 19·3–34·5), with less than 
200 cells per μL was 19·5% (95% CI 15·4–24·1), and 
200 or more cells per μL was 13·3% (95% CI 8·9–18·9).
Complete sets of smear microscopy, culture, and 
Xpert MTB/RIF tests (from one or both sputum 
samples) and urine LAM ELISA and urine Determine 
TB-LAM results were available from a total of 
516 patients (ﬁ gure 1). All subsequent analyses were 
based on these 516 patients, of whom 85 had culture-
positive tuberculosis and 431 had sputum cultures 
negative for M tuberculosis. Additionally, non-
tuberculous mycobacteria were cultured from samples 
of eight patients with CD4 counts of 0–99 cells per μL 
(four), 100–199 cells per μL (three), and 200 or more 
cells per μL (one). All eight also tested negative for 
M tuberculosis with the Xpert MTB/RIF assay.
The study participants were mostly young adults, of 
whom most were female (table 1). The median CD4 cell 
count was 169·5 cells per μL (IQR 100–233), about 
two-thirds of patients had a CD4 cell count of less than 
200 cells per μL, and about a third of patients were 
assessed as having WHO stage 3 or stage 4 (AIDS) 
disease before tuberculosis screening (table 1). Patients 
diagnosed with tuberculosis had lower CD4 cell counts 
and were more likely to have advanced WHO stage of 
disease than were those with higher CD4 cell counts 
(table 1). A positive WHO symptom screen was recorded 
in over two-thirds of all study participants and most 
patients with tuberculosis. Radiological abnormalities 
consistent with pulmonary tuberculosis were seen in just 
three-quarters of patients with tuberculosis but were also 
seen in about two-ﬁ fths of patients without tuberculosis.
We compared the two independently observed readings 
of the Determine TB-LAM urine test strips for 
516 patients. Examples of the developed test strips are 
shown for three patients in ﬁ gure 2. All test strips had 
a positive control bar and were therefore readable. 
The proportionate agreement between the readers was 
514 (99·6%, 95% CI 98·6–100) of 516 (κ 0·97, 95% CI, 
0·88–0·99). The two discrep ancies were resolved by 
consensus with the two observers remaining masked to 
the other laboratory results.
Positive Determine TB-LAM results were noted in 
24 samples from patients with culture-positive tuber culosis 
with a median optical density above background of 0·681 
(IQR 0·164–2·431; range 0·102–3·291). Among patients 
with culture-negative sputum samples (431), six had 
positive test-strip results whereas the remaining 
425 samples were negative. The proportionate agreement 
between the TB-ELISA and urine test strips was 507 (98·3%; 
95% CI 96·7–99·2) of 516 (κ statistic 0·84, 95% CI 
602 eligible patients enrolled 
7 had no urine samples
595 had urine samples
60 had sputum unobtainable
535 with 1039 sputum samples and 535 urine samples 
   1 had two contaminated culture samples
25 had one contaminated culture sample
18 had either no Xpert tests done or they 
       were inconclusive
516 had complete set of LAM ELISA, Determine 
         TB-LAM Ag dipstick, ≥1 microscopy, ≥1 Xpert, 
         and ≥1 culture results 
           28 each had  only one sputum culture result 
        488 each had two sputum culture results 
   431 had no tuberculosis diagnosis conﬁrmed 
            by ≥1 negative culture result 
85 had tuberculosis diagnosis conﬁrmed by 
       ≥1 positive culture
Figure 1: Study proﬁ le
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0·72–0·92), suggesting very good agreement. Of the nine 
discordant results, three were for patients with culture-
positive tuberculosis (ELISA-negative vs Determine-
positive [one] and ELISA-negative vs Determine-positive 
[two]). The six other discordant results were from those 
who were sputum culture-negative (ELISA-positive vs 
Determine-negative [ four] and ELISA-negative vs 
Determine-positive [two]). Thus, the Determine TB-LAM 
assay had marginally higher sensitivity and speciﬁ city than 
did the TB-ELISA assay.
Compared with the gold standard of automated 
liquid culture, the overall sensitivity of sputum-smear 
microscopy was low, as were the sensitivities of both 
the TB-ELISA and Determine TB-LAM strip test 
(table 2). The speciﬁ cities of the three assays, however, 
each exceeded 98% (table 3). Overall sensitivity was 
modestly increased when smear microscopy and the 
Determine TB-LAM strip test were used in combination 
(either test positive), while retaining high speciﬁ city 
(both tests negative).
The potential usefulness of the Determine TB-LAM 
assay was evident in patients with advanced immuno-
deﬁ ciency when data were stratiﬁ ed by CD4 cell count 
(table 2). The assay correctly identiﬁ ed more than two-
thirds of tuberculosis cases with CD4 counts less than 
50 cells per μL and about half of cases with counts less 
than 100 cells per μL. When use was expanded to also 
include patients with higher CD4 cell counts, the 
sensitivity gradually declined and was very low above a 
threshold of 200 cells per μL (table 2). However, when 
Determine TB-LAM strip tests were used in combination 
with smear microscopy (either test positive), an 
important additive eﬀ ect occurred: sensitivities for 
patients with CD4 counts less than 50, less than 100, 
and less than 200 cells per μL were increased. The 
speciﬁ city (both tests negative) across all strata was 98% 
or higher.
We also calculated the sensitivity of Determine TB-
LAM strip tests for culture-positive patients with WHO 
All patients (n=516) Tuberculosis diagnosed (n=85) No tuberculosis diagnosed (n=431) p value
Age 34·1 (28·6–41·3) 33·4 (28·7–40·7) 34·1 (28·5–41·3) 0·806
Female 331 (64%) 52 (61%) 279 (65%) 0·532
BMI 23·5 (20·9–27·1) 21·2 (19·3–25·9) 23·9 (21·1–27·2) 0·0001
CD4 counts (cells per μL)* 169·5 (100–233) 139 (65·5–205) 172 (108–237) 0·006
<50 64 (12%) 18 (21%) 46 (11%) 0·064
50–99 64 (12%) 11 (13%) 53 (12%) ··
100–149 96 (19%) 17 (20%) 79 (18%) ··
150–199 101 (20%) 13 (15%) 88 (20%) ··
≥200 189 (37%) 25 (30%) 164 (38%) ··
Baseline viral load (log copies per mL)† 4·6 (4·1–5·0) 4·8 (4·4–5·3) 4·5 (4·0–5·0) 0·0001
WHO stage at enrolment
1 or 2 346 (67%) 47 (55%) 299 (69%) 0·012
3 or 4 170 (33%) 38 (45%) 132 (31%) ··
Positive WHO symptom screen 356 (69%) 70 (82%) 286 (66%) 0·004
Previous history of tuberculosis 140 (27%) 19 (22%) 121 (28%) 0·278
Current cough ≥2 weeks 104 (20%) 21 (25%) 83 (19%) 0·252
Radiological abnormality consistent 
with tuberculosis‡
235 (50%) 62 (76%) 173 (45%) <0·0001
Data are median (IQR) or number (%). BMI=body mass index. *CD4 cell counts available for 84 patients with tuberculosis and 430 patients without tuberculosis. †Viral loads 
were available for 513 patients. ‡Chest radiographs were available for 470 patients.
Table 1: Patient characteristics
Figure 2: Determine TB-LAM test strips from three patients in this study 
together with the reference reading card
Positive control (upper) bands are seen in all three strips whereas positive test 
(lower) bands are only seen in the middle and right hand strips and the left 
strip is negative.
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stage 3 or 4 disease (46·0%; 95% CI 29·5–63·1), a positive 
WHO symptom screen (31·4%; 95% CI, 20·9–43·6), and 
for those with an abnormal chest radiograph (27·9%; 
95% CI 17·1–40·8). When Determine TB-LAM test strips 
and smear-microscopy results were combined (either test 
positive), the sensitivities for these three groups were 
59·5% (stage 3 or 4), 48·6% (positive symptom screen), 
and 45·9% (abnormal chest radiograph). In all these 
subgroup analyses, the speciﬁ city of the tests for culture-
negative patients was greater than 98% for each subgroup 
with the Determine TB-LAM test alone or combined with 
smear microscopy (table 3).
Among six patients with negative sputum cultures for 
M tuberculosis but whose urine samples tested positive 
with Determine TB-LAM, all had sputum samples 
that tested negative with the Xpert MTB/RIF assay. 
Extrapulmonary tuberculosis was not clinically suspected 
in any of the six patients at the time of screening, but 
non-tuberculous mycobacteria were cultured from 
sputum samples from two of them. Only two of these 
patients had a CD4 cell count less than 150 cells per μL or 
WHO stage 3 or 4 disease—the subgroups in which the 
assay has the greatest usefulness.
To further assess the eﬀ ectiveness of Determine 
TB-LAM in diﬀ erent patient subgroups with diﬀ ering 
prevalence of tuberculosis, we calculated the positive 
predictive and negative predictive values when using the 
test alone or combined with smear microscopy (table 4). 
When Determine TB-LAM was applied to all patients 
irrespective of their characteristics, the positive predictive 
value was lower than if selectively applied to patients with 
CD4 cell counts in the range 0–150 cells per μL or to 
patients with WHO stage 3 or 4 disease. In all sub groups, 
the negative predictive value varied sub stantially 
(table 4).
When the results of Determine TB-LAM were com bined 
with those of smear microscopy, the positive predictive 
value when testing unselected patients was lower than 
when applied to patients with CD4 cell counts in the range 
0–150 cells per μL and for those with WHO stage 3 or 
4 disease and radiographic abnormalities (table 4).
We next compared the diagnostic eﬀ ectiveness of the 
Determine TB-LAM test strips and smear microscopy 
with that of the Xpert MTB/RIF assay. When screening 
all patients irrespective of CD4 cell count, the sensitivity 
and speciﬁ city of the Xpert MTB/RIF when testing a 
single sputum sample was greater than the Determine 
TB-LAM test strips and microscopy (tables 2, 3, ﬁ gure 3). 
However, when screening patients with advanced 
immunodeﬁ ciency, the combined sensitivity of 
Determine TB-LAM test strips and smear microscopy 
combined (either test positive) did not diﬀ er signiﬁ cantly 
from that of the Xpert MTB/RIF assay for patients with 
CD4 cell counts less than 50 cells per μL or less than 
100 cells per μL (ﬁ gure 3, table 2). A small increment in 
sensitivity was also seen when results from both Xpert 
MTB/RIF and Determine TB-LAM were combined 
(ﬁ gure 3, table 2).
Sputum AFB TB ELISA Determine TB-LAM Determine TB-LAM and 
sputum AFB
Xpert MTB/RIF 
(1 sample)
Determine TB-LAM and 
Xpert MTB/RIF
Positive Sensitivity Positive Sensitivity Positive Sensitivity Positive Sensitivity Positive Sensitivity Positive Sensitivity
All (n=85) 24 28·2% 
(19·0–39·0)
23 27·1% 
(18·0–37·8)
24 28·2% 
(19·0–39·0)
37 43·5% 
(32·8–54·7)
49 57·6% 
(46·4–68·3)
52 61·2% 
(50·0–71·6)
<50 cells per μL 
(n=18)
6 33·3% 
(13·3–59·0)
11 61·1% 
(35·7–82·7)
12 66·7% 
(41·0–86·7)
13 72·2% 
(46·5–90·3)
13 72·2% 
(46·5–90·3)
15 83·3% 
(58·6–96·4)
<100 cells per μL 
(n=29)
10 34·5% 
(17·9–54·3)
14 48·3% 
(29·4–67·5)
15 51·7% 
(32·5–70·6)
19 65·5% 
(45·7–82·1)
22 75·9% 
(56·5–89·7)
24 82·8% 
(64·2–94·2)
<150 cells per μL 
(n=46)
16 34·8% 
(21·4–50·2)
20 43·5% 
(28·9–58·9)
21 45·7% 
(30·9–61·0)
27 58·7% 
(43·2–73·0)
33 71·7% 
(56·5–84·0)
35 76·1% 
(61·2–87·4)
<200 cells per μL 
(n=59)
18 30·5% 
(19·2–43·9)
21 35·6% 
(23·6–49·1)
23 39·0% 
(26·5–52·6)
31 52·5% 
(39·1–65·7)
37 62·7% 
(49·1–75·0)
40 67·8% 
(54·4–79·4)
≥200 cells per μL 
(n=25)
6 24·0% 
(9·4–45·1)
2 8·0% 
(1·0–26·0)
1 4·0% 
(0·1–20·4)
6 24·0% 
(9·4–45·1)
11 44·0% 
(24·4–65·1)
11 44·0% 
(24·4–65·1)
84 patients stratiﬁ ed by CD4 cell count. Data are number and sensitivity (95% CI). AFB=acid-fast bacilli. LAM=lipoarabinomannan. MTB/RIF=Mycobacterium tuberculosis/rifampicin.
Table 2: Sensitivity of the diﬀ erent diagnostic assays for all patients with tuberculosis and for those stratiﬁ ed by CD4 cell count
Sputum AFB ELISA Determine TB-LAM Determine TB-LAM and 
sputum AFB
Xpert MTB/RIF (1 sample) Determine TB-LAM and 
Xpert MTB/RIF
Negative Speciﬁ city Negative Speciﬁ city Negative Speciﬁ city Negative Speciﬁ city Negative Speciﬁ city Negative Speciﬁ city
All (n=431) 430 99·8% 
(98·7–100)
423 98·1% 
(96·4–99·2)
425 98·6% 
(97·0–99·5)
424 98·4% 
(96·7–99·3)
427 99·1% 
(97·6–99·7)
421 97·7% 
(95·8–98·9)
Data are number and sensitivity (95% CI). AFB=acid-fast bacilli. TB=tuberculosis. LAM=lipoarabinomannan. MTB/RIF=Mycobacterium tuberculosis/rifampicin.
Table 3: Speciﬁ city of the diﬀ erent diagnostic assays for all patients with tuberculosis whose cultures were negative
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Of 516 patients included in the analysis, 478 had data 
available for Xpert MTB/RIF tests on two sputum 
samples. In this group of patients, the sensitivity of 
Determine TB-LAM and smear microscopy combined 
was 41·0% (95% CI 30·0–52·7) versus 66·7% 
(55·1–76·9) for Xpert MTB/RIF (two samples; p=0·002). 
Among 115 patients with CD4 counts less than 
100 cells per μL, the sensitivities were 62·5% (95% CI 
40·6–81·2) for Determine TB-LAM and smear micro-
scopy combined and 79·2% (57·8–92·9) for Xpert 
MTB/RIF with two samples (p=0·34). Moreover, in this 
subset, the sensitivity of Determine TB-LAM and Xpert 
MTB/RIF (one sample) was identical to that of 
Xpert MTB/RIF (two samples) both 79·2% (95% CI 
57·8–92·9). In all these subanalyses, speciﬁ city was 
98% or higher.
Discussion
The Determine TB-LAM lateral-ﬂ ow urine antigen test 
was simple to use with extremely high inter-observer 
agreement between two independent readers. Compared 
with a diagnostic gold standard of liquid culture of 
sputum samples, the assay was useful for screening for 
pulmonary tuberculosis in patients with advanced HIV-
associated immunodeﬁ ciency in this very high burden 
setting (panel). Speciﬁ city of the assay was high in all 
analyses (table 3), including those relating to a range of 
subgroups. Sensitivity was strongly associated with 
patients’ CD4 cell count, with the highest sensitivity 
recorded for those less than 50 cells per μL—the very 
patients for whom rapid diagnosis is most urgently 
needed. An important additive eﬀ ect occurred when 
results were combined with sputum smear microscopy 
(table 2). These combined results in patients with very 
low CD4 counts were similar to the sensitivity obtained 
when testing one sputum sample with the Xpert 
MTB/RIF assay.
The prevalence of tuberculosis in this and other ART 
cohorts in southern Africa3,9,13 is very high. About a third 
of patients referred to the ART service in Gugulethu 
township and other ART clinics in South Africa had a 
pre-existing tuberculosis diagnosis and so were ineligible 
for inclusion.27 However, such patients had a very similar 
proportion of smear-positive disease to that detected in 
the patients we diagnosed (32% vs 28%), suggesting little 
selection bias with regard to the type of tuberculosis.28 
We screened all patients irrespective of the presence or 
absence of symptoms and reported a high prevalence of 
TB prevalence Determine TB-LAM Determine TB-LAM and sputum AFB*
Positive predictive value Negative predictive value Positive predictive value Negative  predictive value
All patients (n=516) 16·5% (13·4–20·0) 80·0% (61·4–92·3) 87·4% (84·2–90·3) 84·1% (69·9–93·4) 89·8% (86·7–92·4)
CD4 cell count (cells per μL)†
<50 28·1% (17·6–40·8) 92·3% (64·0–99·8) 90·2% (78·6–96·7) 92·9% (66·1–99·8) 90·0% (78·2–96·7)
<100 22·7% (15·7–30·9) 93·8% (69·8–99·8) 87·5% (79·9–93·0) 95·0% (75·1–99·9) 90·7% (83·6–95·5)
<150 20·5% (15·4–26·4) 91·3% (72·0–98·9) 87·6% (82·2–91·8) 93·1% (77·2–99·2) 90·3% (85·2–94·0)
<200 18·2% (14·1–22·8) 88·5% (69·8–97·6) 88·0% (83·7–91·4) 88·6% (73·3–96·8) 90·3% (86·3–93·5)
≥200 13·2% (8·7–18·9) 66·7% (9·4–99·2) 87·1% (81·4–91·6) 75·0% (34·9–96·8) 89·5% (84·1–93·6)
WHO stage
Stage 1 or 2 13·6% (10·2–17·7) 63·6% (30·8–89·1) 88·0% (84·1–91·3) 78·9% (54·4–93·9) 90·2% (86·4–93·2)
Stage 3 or 4 22·4% (16·3–29·4) 94·4% (72·7–99·9) 86·8% (80·3–91·7) 91·7% (73·0–99·0) 89·7% (83·5–94·1)
WHO symptom screen
Positive 19·7% (15·7–24·2) 84·6% (65·1–95·6) 85·4% (81·1–89·0) 87·2% (72·6–95·7) 88·6% (84·6–91·9)
Negative 9·4% (5·3–15·0) 66·7% (9·4–99·2) 92·3% (86·9–96·0) 75·0% (19·4–99·4) 93·5% (88·4–96·8)
Any chest-radiograph abnormality‡ 26·4% (20·9–32·5) 85·0% (62·1–96·8) 79·4% (73·4–84·6) 90·3% (74·2–98·0) 83·7% (77·9–88·5)
Data are % (95% CI) or positive or negative predictive value (95% CI). AFB=acid-fast bacilli. TB=tuberculosis. LAM=lipoarabinomannan. *When assessing the predictive values of combined results of Determine 
TB-LAM and smear microscopy, the positive predictive value was based on either test being positive, and the negative predictive value was based on both tests being negative. †514 patients. ‡470 patients.
Table 4: Positive and negative predictive values of Determine TB-LAM or Determine TB-LAM and smear microscopy combined when applied to diﬀ erent patient subgroups with diﬀ ering 
tuberculosis prevalence
Liquid 
culture
Liquid 
culture
Determine TB-LAM
Determine TB-LAM
Sputum AFBSputum AFB
Xpert 
MTB/RIF
Xpert 
MTB/RIF
(39%)
(4%)
(12%)
(13%)
(15%)
(18%)
(17%)
(7%)
(24%)
(21%)
(14%)
(17%)
BA
Figure 3: Venn diagrams showing the proportions of patients diagnosed by sputum culture, Xpert MTB/RIF 
(1 sample), sputum-smear microscopy (sputum acid-fast bacilli), and Determine TB-LAM
Mutually exclusive proportions of patients shown in each of the compartments. Proportions of all patients 
with tuberculosis (A; n=85). Proportions of patients with CD4 cell counts less than 100 cells per μL (B; n=29). 
AFB=acid-fast bacilli.
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sputum culture-positive pulmonary tuberculosis in 
patients with CD4 counts less than 200 cells per μL. In 
view of this ﬁ nding and the limited sensitivity of symptom 
screening tools, microbiological testing for tuberculosis 
has been suggested for all HIV-infected patients in such 
high-burden settings before starting ART, regardless of 
the presence or absence of symptoms.3,9,13 To date, 
however, the high cost of culture, limited laboratory 
capacity, the challenges of safely obtaining sputum 
samples in the clinic environment, and the administrative 
challenges associated with linking results from 
centralised laboratories with patients’ records in over-
stretched clinical services have made application of such 
a policy diﬃ  cult. Moreover, availability of routine culture-
based diagnosis of tuberculosis is extremely poor in sub-
Saharan Africa and new alternative diagnostic strategies 
are clearly needed.
Studies done in countries with high tuberculosis 
burden have shown that diagnostic tests that detect urine 
LAM have the greatest potential usefulness in HIV-
infected patients with advanced immunodeﬁ ciency such 
as those admitted to hospital and those enrolling to start 
ART.13,14 However, this test is in the format of a 96-well 
ELISA assay and requires that urine samples undergo 
initial processing with incubation at 95–100°C for 30 min 
followed by high-speed centri fugation. Thus, the assay 
can only be done in a laboratory setting and with batched 
sample processing. The Determine TB-LAM test strips 
therefore provide a substantial advance. The test strips 
provided sensitivity and speciﬁ city that was comparable 
with the laboratory-based tuberculosis ELISA and results 
were also extremely consistent with those obtained in 
previous studies.13,14 No prior sample processing is 
required and the simple lateral-ﬂ ow format of the assay 
can be very readily used on a per-patient basis at the 
point-of-care by health-care personnel with no laboratory 
training. Results are read after 25 min incubation and so 
can be available during a single clinic visit. The assay is 
applied to urine samples, which are easy to obtain, have 
low biohazard risk, and do not generate infectious 
aerosols as is the problem with sputum expectoration. 
Test strips do not need refrigerated storage and the assay 
does not generate large amounts of biohazardous waste.
Less than a third of tuberculosis cases could be 
diagnosed by sputum-smear microscopy. However, 
combination of results from Determine TB-LAM tests 
strips and sputum-smear microscopy improved diagnosis 
of tuberculosis (table 2). Determine TB-LAM could very 
easily be added into the diagnostic algorithm in settings 
where smear microscopy remains the only micro-
biological test available and would provide important 
incremental sensitivity.
The positive predictive value of Determine TB-LAM 
when used alone or in combination with sputum-smear 
microscopy was high for patients with CD4 counts less 
than 150 cells per μL and in those with WHO stage 3 or 
4 disease but was low when the test was applied to patients 
with less advanced immunodeﬁ ciency. The negative 
predictive value of the assay was not suﬃ  ciently high to 
rule out a diagnosis of tuberculosis. Thus, the assay 
should be restricted for use as a test for tuberculosis in 
patients with advanced immunodeﬁ ciency. These are the 
patients in whom tuberculosis diagnosis is so challenging 
such that, in the absence of suitable diagnostic assays, 
empirical treatment has been suggested as a strategy to 
reduce the high mortality of patients with very low CD4 
cell counts in settings with the highest disease burden.29 
However, with the development of this simple point-of-
care assay, such a strategy might prove unnecessary. 
Studies of the use of this assay and its eﬀ ects on clinical 
outcomes in such patient groups are now needed.
The eﬀ ectiveness of this moderate sensitivity assay is 
dependent on high speciﬁ city. Five studies of various 
versions of the TB LAM-ELISA in South Africa and 
Tanzania have all reported high speciﬁ city 
(96–100%).13–16,19 However, two other studies from sub-
Saharan Africa have shown much lower speciﬁ cities.17,18 
The reason for this heterogeneity is unknown, but it 
could be related to study design, setting, or sensitivity 
of the laboratory gold standard (mycobacterial culture) 
for tuberculosis diagnosis. No study has reported cross-
reactivity with non-tuberculous myco bacteria as a cause 
for lowered speciﬁ city although we reported that such 
bacteria were associated with two false-positives. 
Further studies are urgently needed to assess diagnostic 
accuracy in other settings and to establish whether the 
assay can be used in isolation for reliable rapid 
tuberculosis diagnosis or whether conﬁ rmatory tests 
are subsequently needed.
Panel: Research in context
Systematic review
We searched PubMed for articles published between Jan 1, 
1990, and August 1, 2011, with the key words “tuberculosis”, 
“diagnosis”, and “lipoarabinomannan”. We included original 
research studies that provided data about the diagnostic 
accuracy of commercially available diagnostic assays that 
detect lipoarabinomannan (LAM) in urine for the diagnosis of 
tuberculosis in HIV-infected patients.
Interpretation
Our study is the ﬁ rst to assess the eﬀ ectiveness of a simple 
lateral-ﬂ ow point-of-care assay for detection of urinary LAM 
for the diagnosis of tuberculosis during routine screening of 
HIV-infected patients. The point-of-care version of the assay 
had diagnostic accuracy consistent with that recorded when 
urine samples from HIV-infected individuals with advanced 
immunodeﬁ ciency were tested with a laboratory-based ELISA, 
but it was much easier to use, providing results within 25 min 
without need for equipment or laboratory training. The assay 
is likely to be useful as a rapid point-of-care tuberculosis 
diagnostic method in this group of patients.
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In this clinical setting, we have previously reported that 
the Xpert MTB/RIF assay had sensitivities of 58% when 
testing one sputum sample and 78% when testing two 
samples. However, even the cost of one cartridge (US$18 
at the time of the study) would represent the annual total 
health spending per head in many poor countries.30 The 
Determine TB-LAM assay is currently marketed at about 
$3·50 per test strip and thus the use of this simple test in 
combination with smear microscopy is a low-cost 
alternative that has similar sensitivity to a single Xpert 
MTB/RIF test for patients with CD4 counts less than 
200 cells per μL. In settings in which the Xpert MTB/RIF 
assay is implemented, the cost of two Xpert MTB/RIF 
tests to gain incremental sensitivity might be prohibitively 
expensive. However, a single Xpert MTB/RIF test might 
alternatively be used in combination with a Determine 
TB-LAM test because this combination had identical 
sensitivity to two Xpert MTB/RIF tests in those with CD4 
counts less than 100 cells per μL.
The strengths of this study include the assessment of 
Determine TB-LAM in a well characterised community-
based ART service in the public sector, which is similar to 
other services in southern Africa. The assay was compared 
with a range of other tests including a rigorous gold 
standard for pulmonary tuberculosis (ie, automated liquid 
culture of sputum done in an accredited laboratory with 
rigorous quality assurance procedures). Sputum samples 
could not be obtained from 10% of enrolled patients, and 
in the absence of the diagnostic gold standard these 
patients were excluded from the analysis. The results 
therefore cannot be generalised to apply to this subgroup.
Although tuberculosis diagnoses can be established 
from sputum culture for most patients with advanced 
HIV-associated immunodeﬁ ciency,31 a few require extra-
pulmonary samples. Since no additional tests were done 
for extrapulmonary tuberculosis, the speciﬁ city of the 
urine LAM assays could have been underestimated or 
the sensitivity overestimated. Patients were carefully 
screened at a single timepoint but follow-up of clinical 
outcomes was not included in the deﬁ nition of 
tuberculosis cases. We did not include these outcomes 
because the clinical presentation of tuberculosis is so 
non-speciﬁ c in this population and the ongoing incidence 
of the disease is so high that the distinction between 
prevalent and incident tuberculosis can only be reliably 
made with speciﬁ c microbiological endpoints in samples 
obtained at the time of initial screening.32
Although LAM is a stable lipopolysaccharide and sample 
freezing is acceptable before testing by the tuberculosis 
ELISA, the eﬀ ect of freezing and thawing of the urine 
samples before testing with Determine TB-LAM was not 
assessed. Determine TB-LAM testing was not done at the 
actual point-of-care and results were not used to direct 
management of patients. Thus, the eﬀ ect of the assay on 
outcomes is not known. Further prospective assessments 
of this new assay at the point-of-care are needed in 
diﬀ erent settings as is assessment of cost-eﬀ ectiveness.
Determine TB-LAM test was very easy to use and is 
readily applicable as a point-of-care diagnostic test for 
HIV-associated tuberculosis when screening patients 
with advanced immunodeﬁ ciency. This test is an 
important low-cost alternative diagnostic test for this 
group of patients for use in resource-limited settings.
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